CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

Human Chronic Myelogenous Leukemia (CML) is a hematological stem cell disorder which is associated with activation of Bcr-Abl-Stat5 oncogenic pathway. Direct Bcr-Abl inhibitors are initially successful for the treatment of CML but over time many patients develop drug resistance. In the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Borja, Martín-Rodríguez, Patricia, Díaz-Chico, Juan Carlos, McNaughton-Smith, Grant, Jiménez-Alonso, Sandra, Hueso-Falcón, Idaira, Montero, Juan Carlos, Blanco, Raquel, León, Javier, Rodríguez-González, Germán, Estévez-Braun, Ana, Pandiella, Atanasio, Díaz-Chico, Bonifacio Nicolás, Fernández-Pérez, Leandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444695/
https://www.ncbi.nlm.nih.gov/pubmed/27557509
http://dx.doi.org/10.18632/oncotarget.11425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444695/
https://www.ncbi.nlm.nih.gov/pubmed/27557509
http://dx.doi.org/10.18632/oncotarget.11425

Ejemplares similares